Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS1590 is a **polyunsaturated side-chain analogue of vitamin D3**, classified as a small molecule drug. It functions primarily as a **brain-derived neurotrophic factor (BDNF) agonist** and **nerve growth factor (NGF) stimulant**, with neuro-stimulant properties. In research, GS1590 has demonstrated suppression of **parathyroid hormone (PTH) secretion** and reduction of PTH mRNA levels in parathyroid cells, suggesting utility in treatment or prevention of secondary hyperparathyroidism (HPT) in chronic renal failure, as well as possible utility in nervous system diseases. The analogue was originally developed by Cephalon and later investigated by LEO Pharma[1][13][16].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GS1590.